Gene

EGFR

epidermal growth factor receptor

Explore in graph →CI-GENE-00044375HGNC:3236 ENSG00000146648 NCBI 1956 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (644)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–50 of 644 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BRAF V600E + EGFR L858R + EGFR T790MEGFR BRAF1
Osimertinib	Lung Adenocarcinoma	Predictive	C	Supports Resistance

Cohorts

Alteration frequency by cohort (195)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved195 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Lung Adenocarcinoma (MSK, 2021) luad_mskimpact_2021	Lung Adenocarcinoma	Ssm	183	186	98.4%

Literature

Linked publications (141)

25 per page, newest first.

pubmedPublishedShowing 1–25 of 141 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

EGFR T790M resistance mutation in non small-cell lung carcinoma.
· Clin Chim Acta · 2015 · PMID 25668228 · validated civic_curation pubmed
Osimertinib: First Global Approval.
· Drugs · 2016 · PMID 26729184 · validated civic_curation pubmed
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
· N Engl J Med · 2017 · PMID 27959700 · validated civic_curation pubmed
U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.
· Oncologist · 2014 · PMID 24868098 · validated civic_curation

Positive + EGFR e10::e181
(oncogenic)	Pediatric GliomaUNRESOLVED	Oncogenic	C	Supports Oncogenicity	1	submitted	EID11169 Big sequencing study (WGS and RNAseq) performed on 252 high-risk pediatric tumors. One pediatric glioma case was identified with chromothripsis affecting chromosome 7 and likely resulting in formation… (full text at CIViC) PMID 33020650 · Wong et al., 2020 · Open in CIViC	civic

Positive + EGFR e10::e181

(oncogenic)

Pediatric GliomaUNRESOLVED

Oncogenic

Supports Oncogenicity

submitted

EID11169

Big sequencing study (WGS and RNAseq) performed on 252 high-risk pediatric tumors. One pediatric glioma case was identified with chromothripsis affecting chromosome 7 and likely resulting in formation… (full text at CIViC)

PMID 33020650 · Wong et al., 2020 · Open in CIViC

EGFR A289V2
(functional)	—UNRESOLVED	Functional	D	Supports Gain Of Function	4	submitted	EID10069 In an in vitro study, EGFR ectodomain missense mutants (T263P, A289V, G598V, L861Q) were expressed in human immortalized astrocytes and BaF3 cells. Phosphorylation was measured via immunoblot. All ect… (full text at CIViC) PMID 17177598 · Lee et al., 2006 · Open in CIViC	civic
Erlotinib	High-Grade Glioma, NOS	Predictive	D	Supports Sensitivity Response	3	accepted	EID4188 In an in vitro study, a Ba/F3 cell line expressing EGFR A289V demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assesse… (full text at CIViC) PMID 17177598 · Lee et al., 2006 · Open in CIViC	civic

EGFR A763_Y764insFQEA7
Erlotinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	2	submitted	EID5939 Out of a group of 19 EGFR exon 20 insertion NSCLC patients, 3 patients had EGFR M766_A767insASV mutation. One patient was 69 year old female neversmoker lung adenocarcinoma patient was given erlotini… (full text at CIViC) PMID 24353160 · Yasuda et al., 2013 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	1	submitted	EID11320 In this study, 4 patients with an EGFR exon 19 insertion and 6 patients with an EGFR exon 20 insertion (A763_Y764insFQEA) were enrolled. Hospital. Among patients with an exon 19 insertion, 3 received … (full text at CIViC) PMID 28089594 · Lin et al., 2017 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	—	submitted	EID4647 In a lung adenocarcinoma patient harboring EGFR A763_Y764insFQEA mutation, EGFR A763_Y764insFQEA was associated with partial response to treatment with erlotinib in combination with chemotherapy. PMID 23371856 · Arcila et al., 2013 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	—	submitted	EID4648 In a metastatic non-small cell lung carcinoma patient harboring EGFR A763_Y764insFQEA mutation, EGFR A763_Y764insFQEA was reported to be sensitive to erlotinib treatment. The patient was initially tre… (full text at CIViC) PMID 22270724 · Montagut et al., 2012 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	—	accepted	EID4497 In an in vitro study, Ba/F3 and BID007 cell lines expressing EGFR A763_Y764insFQEA demonstrated increased sensitivity to erlotinib treatment (IC50=0.048�M and 0.082�M, respectively), comparable to Ba/… (full text at CIViC) PMID 24353160 · Yasuda et al., 2013 · Open in CIViC	civic
Afatinib + GefitinibSubstitutes	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	submitted	EID5951 Ba/F3 cells transduced with EGFR A763_Y764insFQEA were IL3 growth independant, suggesting a driver mutation. Gefitinib growth inhibition IC50 in A763_Y764insFQEA transduced Ba/F3 cells was 0.174 micr… (full text at CIViC) PMID 24353160 · Yasuda et al., 2013 · Open in CIViC	civic
Osimertinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	2	accepted	EID9225 In a retrospective study of 2316 Chinese patients with stage IV non-small cell lung carcinoma, a 65 year old female with the EGFR exon 20 insertion A763_Y764insFQEA received osimertinib as second-line… (full text at CIViC) PMID 31208370 · Fang et al., 2019 · Open in CIViC	civic

EGFR A767_V769dupASV6
Dacomitinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	2	submitted	EID12421 In an in vitro study, MCF-7 cells expressing the EGFR A767_V769dup mutation demonstrated sensitivity to dacomitinib (PF00299804), with YFP-EGFR-ICD relocation observed at 10 nM. In comparison, cells e… (full text at CIViC) PMID 21132006 · Harada et al., 2011 · Open in CIViC	civic
Erlotinib	Lung Adenocarcinoma	Predictive	C	Supports Resistance	—	accepted	EID4665 In a study of 19 non-small cell lung carcinoma patients with EGFR exon 20 insertion mutations and treated with erlotinib monotherapy, patients with EGFR A767_V769dupASV mutation (n=3) experienced prog… (full text at CIViC) PMID 24353160 · Yasuda et al., 2013 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	2	submitted	EID5948 Ba/F3 cells transduced with EGFR A767_V769dupASV were IL3 growth independent, suggesting a driver mutation, and did not indicate sensitivity to erlotinib treatment (growth inhibition IC50=2.644 micro … (full text at CIViC) PMID 24353160 · Yasuda et al., 2013 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Resistance	—	submitted	EID4666 In an in vitro study, a MCF-7 cell line expressing EGFR A767_V769dup mutation demonstrated resistance to erlotinib treatment, compared to MCF-7 cells expressing a known erlotinib sensitizing mutation … (full text at CIViC) PMID 21132006 · Harada et al., 2011 · Open in CIViC	civic
Afatinib + GefitinibSubstitutes	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Does Not Support Sensitivity Response	3	submitted	EID5949 Ba/F3 cells transduced with EGFR A767_V769dupASV were IL3 growth independent, suggesting a driver mutation. Gefitinib growth inhibition IC50 in A767_V769dupASV transduced Ba/F3 cells was 2.685 micro … (full text at CIViC) PMID 24353160 · Yasuda et al., 2013 · Open in CIViC	civic
Osimertinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	3	accepted	EID9220 In a retrospective study of 2316 Chinese patients with stage IV non-small cell lung carcinoma, a 63 year old female with the EGFR exon 20 insertion A767_V769dupASV received osimertinib as first-line t… (full text at CIViC) PMID 31208370 · Fang et al., 2019 · Open in CIViC	civic

EGFR Amplification15
(prognostic)	Head and Neck Squamous Cell Carcinoma	Prognostic	B	Supports Poor Outcome	4	accepted	EID473 The group of 43 out of 75 tumor samples with increased copy number or amplification of EGFR as determined by FISH (FISH-positive) had worse progression-free and overall survival than FISH-negative tum… (full text at CIViC) PMID 16943533 · Chung et al., 2006 · Open in CIViC	civic
〃	Barrett AdenocarcinomaALIAS	Prognostic	B	Supports Poor Outcome	3	accepted	EID470 In patients with Barrett's adenocarcinoma, those with amplification of EGFR had shorter disease-specific survial. PMID 20840671 · Marx et al., 2010 · Open in CIViC	civic
〃	Cervical Squamous Cell CarcinomaCURATED_BROADER	Prognostic	B	Supports Poor Outcome	3	accepted	EID471 In patients with cervical squamous cell carcinoma, those with gene amplification of EGFR had worse overall survival. PMID 21730982 · Iida et al., 2011 · Open in CIViC	civic
Cetuximab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID911 87 patients with metastatic colorectal cancer treated with cetuximab were retrospectively analyzed for EGFR amplifications by FISH. In multivariate analysis, EGFR amplification predicted response and … (full text at CIViC) PMID 18794099 · Personeni et al., 2008 · Open in CIViC	civic
〃	Gastric Adenocarcinoma	Predictive	B	Supports Sensitivity Response	3	submitted	EID6927 This retrospective analysis of a Phase 2 trial shows significant association between increased EGFR gene copy number (≥ 4.0) and overall survival (OS) in patients with gastric and oesophago-gastric ju… (full text at CIViC) PMID 22152101 · Luber et al., 2011 · Open in CIViC	civic
Cetuximab + PanitumumabSubstitutes	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID854 In this meta-analysis (14 studies, 1021 patients), EGFR gene copy number (GCN) was predictive of improved progression free survival (PFS) and overall survival (OS) with cetuximab or panitumumab regard… (full text at CIViC) PMID 24653627 · Shen et al., 2014 · Open in CIViC	civic
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID948 A meta-analysis of EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment was performed. In total, 20 (1689 patients, 594 with increased gene copy n… (full text at CIViC) PMID 20826716 · Dahabreh et al., 2011 · Open in CIViC	civic
Erlotinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	submitted	EID7802 Study was a Phase 3 clinical trial of erlotinib in non-small cell lung cancer patients who has progressed after standard chemotherapy. Study found significantly increased survival time for patients… (full text at CIViC) PMID 16014883 · Tsao et al., 2005 · Open in CIViC	civic
Afatinib + Cetuximab + ErlotinibSubstitutes	Head and Neck Squamous Cell Carcinoma	Predictive	D	Does Not Support Sensitivity Response	2	submitted	EID9674 This retrospective preclinical study assessed the efficacies of cetuximab, afatinib, and erlotinib towards head and neck squamous cell carcinoma (HNSCC) & esophageal squamous cell carcinoma (ESCC) cel… (full text at CIViC) PMID 27207775 · Nakamura et al., 2016 · Open in CIViC	civic
Erlotinib + GefitinibSubstitutes	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID5924 The result of the analysis found that EGFR gene copy number was associated with increased OS and PFS, supporting the idea that EGFR gene copy number is a biomarker for response to EGFR-TKI therapy in … (full text at CIViC) PMID 20826716 · Dahabreh et al., 2011 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID5925 Among TKI-treated patients, increased EGFR gene copy number appears to be associated with improved survival outcomes. PMID 27664271 · Zhang et al., 2017 · Open in CIViC	civic
Erlotinib + GefitinibSubstitutes	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Does Not Support Sensitivity Response	2	accepted	EID977 In 290 patients with advanced NSCLC, 177 of which were treated with EGFR TKI (erlotinib or gefitinib). EGFR amplification (Multiplex ligation-dependent probe amplification; MLPA) and Mutation (PCR) we… (full text at CIViC) PMID 26722081 · Fiala et al., 2016 · Open in CIViC	civic
Osimertinib + RociletinibSubstitutes	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Resistance	3	accepted	EID3015 Evidence of wild-type allele-mediated resistance, a novel concept of acquired resistance in response to mutation-selective inhibitor therapy in cancer treatment. This study reports that the Src-AKT pa… (full text at CIViC) PMID 28202511 · Nukaga et al., 2017 · Open in CIViC	civic
Cetuximab + Fluorouracil + Platinum CompoundCombination	Head and Neck Squamous Cell Carcinoma	Predictive	B	Does Not Support Sensitivity Response	4	accepted	EID691 EGFR amplification was not a predictor of response to cetuximab/5-FU/platinum in patients with recurrent or metastatic HNSSC from the EXTREME study. PMID 21048039 · Licitra et al., 2011 · Open in CIViC	civic
Talazoparib	GlioblastomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	4	submitted	EID7785 Preclinical experiments with 27 GBM patient-derived cell lines showed selective sensitivity to the PARP inhibitor talazoparib in EGFR amplified samples relative to EGFR wild-type samples (p<0.0001). F… (full text at CIViC) PMID 31852834 · Wu et al., 2020 · Open in CIViC	civic

EGFR AUTOCRINE ACTIVATION2
Crizotinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Resistance	2	rejected	EID769 Five patients with acquired resistance to crizotinib showed high concentration of amphiregulin in malignant pleural effusions. PMID 23344087 · Kim et al., 2013 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Resistance	3	rejected	EID768 A cell line (DFCI076 ) with EML1-ALK fusion and resistance mutation L1152R showed no response to ALK inhibition with crizotinib or TAE684. There was co-dependancy on AKT and EGFR-signaling and inhibit… (full text at CIViC) PMID 21791641 · Sasaki et al., 2011 · Open in CIViC	civic